COVID-19

Trinity Biotech Reaches Profitability Inflection Point, Marking Major Milestone in Strategic Turnaround

-Trinity Biotech projects it reached Adjusted EBITDA1 -positive operations during Q2 2025 and expects to be Adjusted EBITDA1 positive going…

6 months ago

Nanox Announces Clinical and Educational Collaboration with Keiser University Featuring the Nanox.ARC

Nanox.ARC delivers advanced 3D imaging with proprietary cold cathode technologyClinical studies show superior diagnostic performance to X-ray with reduced radiation…

6 months ago

Attoplex and KAIST Sign MOU to Develop AI-Based PCR Primer Design Platform for Pandemic Response

Accelerating Commercialization of Early Diagnostic Kits Using "VPrimer" Technology That Covers Over 95% of RNA Virus Mutations SEOUL, South Korea,…

6 months ago

Croom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health Launch

Calgary, Alberta--(Newsfile Corp. - June 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III autologous stem…

6 months ago

Hemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible Debenture

Calgary, Alberta--(Newsfile Corp. - June 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")…

6 months ago

Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity

TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…

6 months ago

SeaStar Medical Reports Update on Nasdaq Listing Status

DENVER, June 25, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming…

6 months ago

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

BERKELEY, Calif. and MAINZ, Germany, June 25, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),…

6 months ago

Arbor Biotechnologies Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors

Former Pfizer Chief Scientific Officer brings decades of drug development and strategic leadership experience to Arbor’s BoardCAMBRIDGE, Mass., June 25,…

6 months ago